Company Profile -
about us

ABOUT US

Profile

Beijing CorreGene Biotechnology Co., Ltd

Beijing CorreGene Biotechnology Co., Ltd.: Pioneering a New Era in TCR Immunotherapy.

Founded by several alumni of Peking University, Beijing CorreGene Biotechnology Co., Ltd. is dedicated to the development of innovative therapeutics based on T-cell receptors (TCRs). The company has established a comprehensive research and development platform for TCR technology, which includes significant breakthroughs in TCR cloning and affinity optimization.

A key highlight is the proprietary SMART-TCR affinity optimization platform, a revolutionary technology that substantially increases the success rate and efficiency of TCR optimization. This groundbreaking platform has effectively overcome previous challenges in developing TCR-based medications.

Currently, CorreGene is at the forefront of developing multiple first-in-class TCR-T cell therapies and TCR bispecifics. These include the pioneering cell therapy drug targeting KRAS-G12 mutations in China and the world's first TCR bispecific targeting HPV infectious diseases. The company's goal is to become a global leader in TCR-based immunotherapies.


Looking to the future, CorreGene aims to pioneer distinct therapeutic modalities of T-cell receptors (TCRs) for Adoptive Cell Transfer (ACT) and Bispecifics, targeting tumor, chronic infection, and autoimmune diseases, with an eye on trillion-dollar markets. This goal not only demonstrates their mastery of technology but also reflects a deep understanding of future medical needs.

Culture

Mission

Transformative biotechnologies grant
the hope of life

Vision

Achieve a trustworthy remarkable biopharmaceutical enterprise

Vision

Achieve a trustworthy remarkable biopharmaceutical enterprise

Core values

Open-minded and collaborative,Boldly innovative,Driven by truth and practicality,Excellence in quality

Core team

Core team

Dr. Xingwang Xie

Founder/Chairman/CEO

With nearly two decades of experience, Dr. Xie is a renowned leader in the field of tumor immunotherapy. He received his training at the pioneering institutions for conducting cellular immunotherapy in China. He also played a pivotal role in China's pioneering clinical trial of a peptide vaccine (NY-ESO-1b) for liver cancer. Dr. Xie is a significant contributor to a series of China's major technological and scientific projects during the 11th, 12th, and 13th Five-Year Plans. He is also a member of the China Anti-Cancer Association and the China Medicinal Biotech Association. Dr. Xie holds a Doctor of Medicine degree from the Chinese Center for Disease Control and Prevention and a Master of Medicine degree from Peking University.


Core team

Dr. Dong Jiang

Co-founder,CTO

With over 20 years of biomedical research experience, significant scientific discoveries have been made in the fields of innate immunity, earning honors such as the Nishiyama Keito Foundation Outstanding Young Scholar in Molecular Virology Research and the Post Doctoral Fellow of the US Hepatitis B Foundation. Dr. Jiang served as a postdoctoral fellow at Drexel University in the United States and as a visiting scholar at Toyama Medical and Pharmaceutical University in Japan. He holds a doctoral degree and a master's degree in medicine from Peking University.

Core team

Dr. JiangHua Wang

Co-founder,CSO

Beijing Science and Technology Rising Star, youth member of the Hepatology Branch of the Beijing Medical Association, youth member of the Asia-Pacific Alliance of Liver Diseases, and an outstanding postdoctoral fellow at the Blumberg Institute of the American Hepatitis B Foundation. Dr. Wang has been extensively involved in the translational research of new antiviral drugs and tumor immunotherapy. As a principal investigator, he has led 5 provincial-level projects and played a key role in more than 10 national major science and technology projects, as well as foundational work projects; He has authored over 20 publications, secured multiple invention patents, and holds a doctor of Medicine degree from the Chinese Center for Disease Control and Prevention, along with a master of Science degree from Peking University.



Core team

Dr. Xueyan Wang

Co-founder,COO

Nearly 20 years of experience in oncology research, an outstanding postdoctoral fellow at Peking University. Dr. Wang participated in the first clinical trial of a peptide vaccine for liver cancer in China, led and participated in more than 10 projects funded by the National Natural Science Foundation of China, the Beijing Natural Science Foundation and the Postdoctoral Foundation, as well as several R&D and clinical trial projects for cellular immunotherapy, tumor-related antigen vaccines and neoantigen vaccines. She hold a doctor of Medicine degree from the Chinese Center for Disease Control and Prevention.


Core team

Professor Yu Wang

Partner,Senior Vice President

Chairman of the China Foundation for Hepatitis Prevention and Control, former Director of the Institute of Hepatology at Peking University Health Science Center, Vice President of Peking University Health Science Center, Deputy Director of China National Center for Biotechnology Development, Deputy Director of the Rural Area and Social Development Office at the Ministry of Science and Technology, and Director of the Chinese Center for Disease Control and Prevention. He participated in and coordinated responses to emerging infectious diseases and major public health emergencies, including human infections with avian influenza and the H1N1 influenza pandemic, organized and led significant public health projects, such as comprehensive tumor prevention and treatment in key regions. His contributions are reflected in numerous research papers published in prestigious journals like The New England Journal of Medicine and The Lancet. He has been awarded the Special Award and the First Award of National Science and Technology Progress, the National Science Fund for Outstanding Youth, and is an expert enjoying the State Council Special Government Allowance. He holds a Doctoral degree in Medicine from Peking University Health Science Center and a doctoral degree in Science from Jichi Medical University in Japan.


Core team

Dr. YongHong Li

Partner,CQO

Former researcher at the National Institutes for Food and Drug Control, an expert on the Drug Registration Review Advisory Committee, and a review expert for the "Critical New Drug R&D" major science and technology project. With over 20 years of experience in biopharmaceutical quality control research, Dr. Li is the main author of the "Overview of Human Gene Therapy Products" in the Chinese Pharmacopoeia, an early contributor to quality control research for CAR-T cell therapy products in China. He has led the research on specifications and test methods for 19 new drugs and participated in on-site GMP inspections for nearly 30 enterprises. He holds a doctor of Science degree from the Air Force Medical University and a master of Medicine degree from the China National Institutes for Drug Control.


Core team

Dr. Weitao Zheng

Partner,Senior Quality Director and Head of EHS

Senior engineer and licensed pharmacist with 23 years of expertise in drug quality management, drug registration and GMP plant construction. Dr. Zheng has taken charge of the construction of a plant for cell therapy products, CMC development, and quality operations, amassing substantial experience in cell product development and quality assurance. Additionally, he actively participated in drafting specifications in the pharmaceutical packaging industry. He holds a master of Science degree from Beijing University of Chemical Technology and is currently pursuing a doctoral degree at Hubei University of Technology.


Core team

Dr. Surui Pei

Partner/Corporate Management Director

Postdoctoral fellow at the Zhongshan Ophthalmic Center, Sun Yat-Sen University, EMBA graduate from Renmin University of China, and recognized as Yiqilin Excellent Talent in the Beijing Economic-Technological Development Area. Dr. Pei brings with her many years of practical experience in product strategy planning and marketing, demonstrating rich expertise in large team management. She has successfully organized over 10 large-scale industry seminars and product launches. Notably, she has been instrumental in incubating products and technologies, including three-generation sequencing microbial detection products, hematological tumor detection products, and ctDNA methylated high-risk screening for eclampsia, among others. Her contributions extend to publishing 15 SCI papers, participating in 5 national studies, and achieving a doctoral degree in science from Ocean University of China and a master's degree in science from Hebei University.


Company history

2023
 
2022
 
2021
 
2020
 
2019
 
2017
 
2016
 
2023
  
2023.11
Won the Second Prize in China (Xiaoshan) High-value Patent Cultivation Competition for the Biomedical Industry
2023.11
Received official approval from the NMPA for clinical trials, marking the formal progression into the registration clinical trial phase
2023.10
Honored to be listed as a Rising Star of “2023 Chinese Healthcare Front-Runners 100”
2023.05
Won the Silver Award in the 17th Beijing Invention and Innovation Competition
2023.05
Rewarded as Fast-growing Companies in 2023 Future Healthcare VB100 Pengcheng Awards
2023.04
Hosted CGT Sub-forum of International Health Industry Forum of Boao Forum for Asia
2023.04
Rewarded as the "Clinical Value Award" and "Annual High-Potential Enterprise" in the 3rd Cool Techs for Oncology (CTO)
2023.03
Won the Excellence Prize in the finals of the “2023 National Disruptive Technology Innovation Competition”, sponsored by the Ministry of Science and Technology (MOST)
2023.03
Rewarded as Specialized in Special New Small and Medium-sized Enterprises  in Beijing
2022
  
2022.08

Won the First Prize in "The First Digital-Intelligent-Innovative Industrial Healthcare Innovation and Entrepreneurship Competition at the 2022 New Industry 50-Person Forum and Life Health Investment and Financing Summit"

2022.08

Rewarded as an intellectual property pilot unit in Beijing


2022.10
Completed series pre-A+ financing of nearly 100 million yuans


2022.11
Won the Special Award in the " Joinnbio · Macromolecular Innovative Pharmaceuticals" Special Competition of 2022 Maker-in-Beijing Innovation and Entrepreneurship Competition
2022.11
Rewarded as Technology Research and Development Organization in Changping District
2022.11

Rewarded as Beijing Postdoctoral Innovation Research Center

2021
  
2021.04

KRAS G12V specific TCR-T CRTKVA11-01 project was officially launched

2021.06
Rewarded as "Zhongguancun High-tech enterprise"
2021.07

Won the certificate of "Director Unit of Gene and Cell Technology Research and Application Commission, National Association of Health Industry and Enterprise Management" (one year period)

2021.08

Winner's Prize of the " Xiuzheng · Pharmaceutics and Health Care Innovation” Special Competition of 2021 Maker-in-Beijing Innovation and Entrepreneurship Competition"

2021.09

Obtained ethical approvals for two IIT clinical trials

2021.09

Top 10 of "2021 Zhongguancun International Frontier Technology Innovation Competition (biomedicine)"

2021.10

Won the certificate of "2021 Top 50 Most Innovative Biomedical Enterprises in China"

2021.11
Completed Series Pre-A financing of nearly 100 million yuans
2021.12
Rewarded as the National High-tech Enterprise
2021.12
Launched new R&D center in Bohui Innovation building with upgraded infrastructure, and GMP manufacturing facility in Origin building
2020
  
2020.10

HPV16 E7 specific TCR-T CRTE7A2-01 project was officially launched, indicating that CorreGene started moving from technology platform development to product development!

2019
  
2019.05

Rewarded as "Zhongguancun High-tech enterprise"

2019.09

R&D center moved into the International Precision Medicine Innovation Center in Singularity Center

2019.12

Received an angel investment of tens of millions (yuan) from Anlong Fund

2017
  
2017.03

Established the first R&D center in Zhongguancun Life Science Park

2017.09

Top 50 in North Promotion of “2017 Maker-in-China Innovation and Entrepreneurship Competition”

2016
  
2016.03

CorreGene was incorporated in Beijing, and began building a R&D platform of TCR innovative therapeutics

2016.05

Rewarded as "Zhongguancun High-tech enterprise"

Qualification & honor

•

Won the Second Prize in China (Xiaoshan) High-value Patent Cultivation Competition for the Biomedical Industry.

•

Honored to be listed as a Rising Star of “2023 Chinese Healthcare Front-Runners 100”

•

Won the Silver Award in the 17th Beijing Invention and Innovation Competition

•

Rewarded as Fast-growing Companies in 2023 Future Healthcare VB100 Pengcheng Awards

•

Rewarded as the "Clinical Value Award" and "Annual High-Potential Enterprise" in the 3rd Cool Techs for Oncology (CTO)

•

Won the Excellence Prize in the Finals of the “2023 National Disruptive Technology Innovation Competition”, sponsored by the Ministry of Science and Technology (MOST)

•

Rewarded as Specialized in Special New Small and Medium-sized Enterprises in Beijing

•

Rewarded as Beijing Postdoctoral Innovation Research Center

•

Rewarded as Technology Research and Development Organization in Changping district

•

Won the Special Award in the " Joinnbio · Macromolecular Innovative Pharmaceuticals" Special Competition of 2022 Maker-in-Beijing Innovation and Entrepreneurship Competition

•

Rewarded as an intellectual property pilot unit in Beijing

•

Won the First Prize in "The First Digital-Intelligent-Innovative Industrial Healthcare Innovation and Entrepreneurship Competition at the 2022 New Industry 50-Person Forum and Life Health Investment and Financing Summit"

•

Rewarded as the National High-tech Enterprise

•

Won the certificate of "2021 Top 50 Most Innovative Biomedical Enterprises in China"

•

Top 10 of "2021 Zhongguancun International Frontier Technology Innovation Competition (biomedicine)"

•

Winner's Prize of the " Xiuzheng · Pharmaceutics and Health Care Innovation” Special Competition of 2021 Maker-in-Beijing Innovation and Entrepreneurship Competition"

•

Top 50 in North Promotion of “2017 Maker-in-China Innovation and Entrepreneurship Competition”

•

Rewarded as "Zhongguancun High-tech enterprise"